Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dannex Ayrton StarwinXGHA:DASPHARMA 4 Buyback Yield % is 0.00 as of Jul. 30, 2026. GuruFocus rates XGHA:DASPHARMA with a GF Score™ of 4/100. The stock has 1 warning sign investors should review. Among 288 Drug Manufacturers companies, Dannex Ayrton Starwin ranks worse than 347221.88% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Dannex Ayrton Starwin Buyback Yield % Related Terms
Dannex Ayrton Starwin Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Dannex Ayrton Starwin's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dannex Ayrton Starwin Buyback Yield % Chart
Dannex Ayrton Starwin Annual Data
Trend
Buyback Yield %
Dannex Ayrton Starwin Semi-Annual Data
Buyback Yield %
XGHA:DASPHARMA vs : Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dannex Ayrton Starwin's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dannex Ayrton Starwin Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dannex Ayrton Starwin's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Dannex Ayrton Starwin's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a Buyback Yield % of 0.00 as of Jul. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Dannex Ayrton Starwin and its competitors. According to the industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 288 companies in the Drug Manufacturers industry.
Is Dannex Ayrton Starwin's Buyback Yield % too high?
Dannex Ayrton Starwin's current Buyback Yield % is 0.00. Based on the distribution chart, Dannex Ayrton Starwin ranks #999999 out of 288 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dannex Ayrton Starwin has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Dannex Ayrton Starwin's Buyback Yield % compare to ?
According to the Drug Manufacturers industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 288 companies for Buyback Yield %. This places Dannex Ayrton Starwin in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Dannex Ayrton Starwin and its competitors. Dannex Ayrton Starwin's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dannex Ayrton Starwin stock overvalued right now?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Dannex Ayrton Starwin's overall GF Score™ is 4/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Dannex Ayrton Starwin (XGHA:DASPHARMA), the current Buyback Yield % is 0.00 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dannex Ayrton Starwin PLC is a pharmaceutical company. The company offers a product range that includes tablets, capsules, liquids syrups and suspensions, powders, ointments, and chemicals. It also manufactures and distributes Vitamin C.
4GF Score
Get the complete analysis for XGHA:DASPHARMA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:DASPHARMA has been successfully added to your 
